168 related articles for article (PubMed ID: 38467144)
21. Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens.
Trujillo-Santos J; Di Micco P; Dentali F; Douketis J; Díaz-Peromingo JA; Núñez MJ; Cañas I; Mastroiacovo D; Saraiva de Sousa M; Monreal M;
Thromb Haemost; 2017 Jan; 117(2):382-389. PubMed ID: 27786333
[TBL] [Abstract][Full Text] [Related]
22. Review of Medical Therapies for the Management of Pulmonary Embolism.
Panahi L; Udeani G; Horseman M; Weston J; Samuel N; Joseph M; Mora A; Bazan D
Medicina (Kaunas); 2021 Jan; 57(2):. PubMed ID: 33530544
[TBL] [Abstract][Full Text] [Related]
23. Treatment of venous thromboembolism.
Wells PS; Forgie MA; Rodger MA
JAMA; 2014 Feb; 311(7):717-28. PubMed ID: 24549552
[TBL] [Abstract][Full Text] [Related]
24. Use of the Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism.
Riva N; Ageno W
Hematol Oncol Clin North Am; 2016 Oct; 30(5):1035-51. PubMed ID: 27637306
[TBL] [Abstract][Full Text] [Related]
25. Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register.
Palareti G; Antonucci E; Legnani C; Mastroiacovo D; Poli D; Prandoni P; Tosetto A; Pengo V; Testa S; Ageno W;
BMJ Open; 2020 Nov; 10(11):e040449. PubMed ID: 33247017
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness and Safety of Oral Anticoagulants in the Treatment of Acute Venous Thromboembolism: A Nationwide Comparative Cohort Study in France.
Bertoletti L; Gusto G; Khachatryan A; Quignot N; Chaves J; Moniot A; Mokgokong R
Thromb Haemost; 2022 Aug; 122(8):1384-1396. PubMed ID: 34983073
[TBL] [Abstract][Full Text] [Related]
27. Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism: A Systematic Review.
Gómez-Outes A; Lecumberri R; Suárez-Gea ML; Terleira-Fernández AI; Monreal M; Vargas-Castrillón E
J Cardiovasc Pharmacol Ther; 2015 Sep; 20(5):490-500. PubMed ID: 25802423
[TBL] [Abstract][Full Text] [Related]
28. Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far?
Voigtlaender M; Langer F
Hamostaseologie; 2017 Oct; 37(4):241-255. PubMed ID: 28508916
[TBL] [Abstract][Full Text] [Related]
29. Treatment of venous thromboembolism in patients with cancer: What news from clinical trials?
Verso M; Franco L; Giustozzi M; Becattini C; Agnelli G
Thromb Res; 2018 Apr; 164 Suppl 1():S168-S171. PubMed ID: 29703477
[TBL] [Abstract][Full Text] [Related]
30. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants.
Ay C; Beyer-Westendorf J; Pabinger I
Ann Oncol; 2019 Jun; 30(6):897-907. PubMed ID: 30918939
[TBL] [Abstract][Full Text] [Related]
31. [Pulmonary embolism and direct oral anticoagulants].
Olschewski H
Wien Med Wochenschr; 2018 Apr; 168(5-6):144-147. PubMed ID: 26983621
[TBL] [Abstract][Full Text] [Related]
32. Expanding Indications of Nonvitamin K Oral Anticoagulants Beyond Nonvalvular Atrial Fibrillation and Venous Thromboembolism: A Review of Emerging Clinical Evidence.
Hajra A; Ujjawal A; Ghalib N; Chowdhury S; Biswas S; Balasubramanian P; Gupta R; Aronow WS
Curr Probl Cardiol; 2024 Jan; 49(1 Pt A):102017. PubMed ID: 37544618
[TBL] [Abstract][Full Text] [Related]
33. [Venous thrombo-embolic disease in cancer. Low molecular weight heparin indications].
Nou M; Laroche JP
J Mal Vasc; 2016 May; 41(3):197-204. PubMed ID: 27146099
[TBL] [Abstract][Full Text] [Related]
34. Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis.
Marik PE; Cavallazzi R
PLoS One; 2015; 10(11):e0143252. PubMed ID: 26587983
[TBL] [Abstract][Full Text] [Related]
35. Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.
Kirkilesis GI; Kakkos SK; Tsolakis IA
Eur J Vasc Endovasc Surg; 2019 May; 57(5):685-701. PubMed ID: 31097186
[TBL] [Abstract][Full Text] [Related]
36. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
Hillis C; Crowther MA
Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
[TBL] [Abstract][Full Text] [Related]
37. Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran.
Leung TS; Law EH
Drug Des Devel Ther; 2015; 9():3557-69. PubMed ID: 26185422
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of outpatient treatment with direct oral anticoagulation in pulmonary embolism.
Ghazvinian R; Gottsäter A; Elf JL
J Thromb Thrombolysis; 2018 Feb; 45(2):319-324. PubMed ID: 29305675
[TBL] [Abstract][Full Text] [Related]
39. Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants.
Vedovati MC; Giustozzi M; Becattini C
Thromb Res; 2019 May; 177():33-41. PubMed ID: 30849513
[TBL] [Abstract][Full Text] [Related]
40. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats.
O'Connell C; Escalante CP; Goldhaber SZ; McBane R; Connors JM; Raskob GE
Oncologist; 2021 Jan; 26(1):e8-e16. PubMed ID: 33275319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
